AMC Stock Forecast, How High Could It Go in 2025 and Beyond?
AMC Entertainment (NYSE:AMC) has been rising lately after years of…
Sell
43
AVTX Quote, Financials, Valuation and Earnings
Last price:
$4.80
Seasonality move
:
-7.64%
Day range:
$4.46 - $4.77
52-week range:
$3.39 - $16.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.30x
P/B ratio:
0.39x
Volume:
66.7K
Avg. volume:
85.4K
1-year change:
-61.03%
Market cap:
$48.4M
Revenue:
$441K
EPS (TTM):
-$3,384.24
Analysts' Opinion
-
Consensus RatingAvalo Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $29.88, Avalo Therapeutics has an estimated upside of 568.35% from its current price of $4.47.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $15.00 representing 100% downside risk from its current price of $4.47.
Fair Value
-
According to the consensus of 6 analysts, Avalo Therapeutics has 568.35% upside to fair value with a price target of $29.88 per share.
AVTX vs. S&P 500
-
Over the past 5 trading days, Avalo Therapeutics has underperformed the S&P 500 by -6.29% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Avalo Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Avalo Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Avalo Therapeutics reported revenues of $192K.
Earnings Growth
-
Avalo Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Avalo Therapeutics reported earnings per share of -$1.25.
Enterprise value:
-76.6M
EV / Invested capital:
--
Price / LTM sales:
1.30x
EV / EBIT:
--
EV / Revenue:
-0.06x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
1.47x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$725K
Return On Assets:
-34.97%
Net Income Margin (TTM):
-1638.65%
Return On Equity:
-375.96%
Return On Invested Capital:
-375.96%
Operating Margin:
-6932.81%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $17.4M | -- | -- | -- | -- | |
| Gross Profit | $14.1M | $796K | $725K | $80K | -- | |
| Operating Income | -$25.4M | -$47.4M | -$50.4M | -$32.8M | -$14.7M | |
| EBITDA | -$25.2M | -$47.3M | -$50.1M | -$32.7M | -$14.5M | |
| Diluted EPS | -$703.00 | -$318.89 | -$3,384.24 | -$141.14 | -$1.25 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $46.1M | $43.7M | $19.3M | $111.2M | $126.9M | |
| Total Assets | $63.3M | $61.9M | $36.2M | $123.7M | $138.5M | |
| Current Liabilities | $26.4M | $17.9M | $23.2M | $215.7M | $5.6M | |
| Total Liabilities | $30.2M | $55.6M | $42.5M | $224.8M | $15.9M | |
| Total Equity | $33.2M | $6.3M | -$6.3M | -$101.1M | $122.6M | |
| Total Debt | -- | $33.2M | $19.8M | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$20.7M | -$26.8M | -$52.3M | -$6.2M | -$9.5M | |
| Cash From Investing | -$228K | $356K | -- | $356K | -- | |
| Cash From Financing | -$951K | $119.9M | $67.2M | $108.6M | -- | |
| Free Cash Flow | -$20.7M | -$26.8M | -$52.3M | -$6.2M | -$9.5M | |
AVTX
Sector
Market Cap
$48.4M
$32.6M
Price % of 52-Week High
27.94%
47.07%
Dividend Yield
0%
0%
Shareholder Yield
-148.61%
-0.74%
1-Year Price Total Return
-61.03%
-37.62%
Beta (5-Year)
0.696
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$4.62
200-day SMA
Sell
Level
$7.91
Bollinger Bands (100)
Sell
Level
4.39 - 7.71
Chaikin Money Flow
Sell
Level
-23.8M
20-day SMA
Buy
Level
$4.25
Relative Strength Index (RSI14)
Buy
Level
50.11
ADX Line
Buy
Level
17.16
Williams %R
Neutral
Level
-37.3239
50-day SMA
Sell
Level
$4.50
MACD (12, 26)
Buy
Level
0.05
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Neutral
Level
33.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.2482)
Sell
CA Score
(Annual)
Level (-2.6046)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (2.3978)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo’s pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Stock Forecast FAQ
In the current month, AVTX has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AVTX average analyst price target in the past 3 months is $29.88.
-
Where Will Avalo Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Avalo Therapeutics share price will rise to $29.88 per share over the next 12 months.
-
What Do Analysts Say About Avalo Therapeutics?
Analysts are divided on their view about Avalo Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Avalo Therapeutics is a Sell and believe this share price will drop from its current level to $15.00.
-
What Is Avalo Therapeutics's Price Target?
The price target for Avalo Therapeutics over the next 1-year time period is forecast to be $29.88 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AVTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Avalo Therapeutics is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AVTX?
You can purchase shares of Avalo Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Avalo Therapeutics shares.
-
What Is The Avalo Therapeutics Share Price Today?
Avalo Therapeutics was last trading at $4.80 per share. This represents the most recent stock quote for Avalo Therapeutics. Yesterday, Avalo Therapeutics closed at $4.47 per share.
-
How To Buy Avalo Therapeutics Stock Online?
In order to purchase Avalo Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Reddit Stock Be In 5 Years?
On a wet March morning last year, the famously orange…
Will Palantir Crash?
AI and data analytics software major Palantir (NASDAQ:PLTR) has been…
Stock Ideas
Buy
65
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 41x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Alerts
Sell
47
RGC alert for Jun 18
Regencell Bioscience Holdings [RGC] is down 19.87% over the past day.
Sell
20
ENPH alert for Jun 18
Enphase Energy [ENPH] is up 3.24% over the past day.
Sell
26
FSLR alert for Jun 18
First Solar [FSLR] is down 0.03% over the past day.
